The coexpression of EGFR (epidermal growth factor receptor) and HER2 in luminal breast cancer is particularly striking, and the combination of HER2 and EGFR blockade has a synergistic effect on tumor lysis because of the ability to overcome compensation via other pathways [60]. The gene discussed is ERBB2; the disease is neoplasm.